A total of 601 patients with a superficial BCC participated in this study: 202 patients were treated with methylaminolevulinate photodynamic therapy (MAL - PDT), 198
with imiquimod cream, and 201 with fluorouracil cream.
While most types of BCC require surgery, superficial BCC can be treated topically with noninvasive treatments such as PDT,
imiquimod cream, fluorouracil cream, cryosurgery or electrodessication and curettage.
More recently, a topical medication
called imiquimod has been used in both canine and human infections to help boost immune - mediated inflammation and thus facilitate destruction of the virus by the body.
Around 80 % of patients with superficial BCC were tumor free
after imiquimod treatment after three years.
Investigators in the Netherlands report the results of a three - year follow - up of a randomized controlled trial that compared three noninvasive treatments that
included imiquimod and fluorouracil cream.
Paeonol
ameliorates imiquimod - induced psoriasis - like skin lesions in BALB / c mice by inhibiting the maturation and activation of dendritic cells.
Some veterinarians see potential in the use of the topical medication immune
modulator imiquimod and the NSAID diclofenac gel.
Peters J, Scott DW, Miller WH (2008) Case Report: Apparent clinical resolution of pinnal actinic keratoses and squamous cell carcinoma in a cat using
topical imiquimod 5 % cream (pending publication in Journal of Feline Medicine and Surgery).
A phase 1 trial of a dendritic cell (DC) vaccine administered
with imiquimod, a TLR7 agonist that stimulates the innate immune system, for patients with malignant glioma and glioblastoma (NCT01808820).
There is also a topical medication
called imiquimod that can be applied to the papilloma or the drug azithromycin can be given orally for treatment.
For example, we have found that in superficial BCC on the lower extremities in older patients, PDT should be prescribed rather than
imiquimod.
«Based on our findings, both
imiquimod and fluorouracil are effective noninvasive treatments in most primary, low - risk superficial BCC, but the data provide no definite evidence for superiority of imiquimod to fluorouracil,» commented Dr. Roozeboom.
However, between one - and three - year follow - up, more recurrences were diagnosed in the fluorouracil group compared with
the imiquimod group.»
Fluorouracil has the advantage of being less expensive than
imiquimod.
A phase 1 trial of a dendritic cell (DC) vaccine administered with
imiquimod, a TLR7 agonist that stimulates the innate immune system, for patients with malignant glioma and glioblastoma -LRB-